VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology - United Kingdom
doi 10.1002/hon.2437_78
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology
Hematology
2018English

Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B- And T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy